Enzyme Inhibitors Market
Number of pages: 100 | Report Format: PDF | Published date: May 15, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
4.1% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global enzyme inhibitors market is expected to register a revenue CAGR of 4.1% during the forecast period.
Enzyme Inhibitors Market Fundamentals
An enzyme inhibitor is a chemical that attaches to an enzyme and inhibits the enzyme's function. Proteins known as enzymes speed up chemical processes where substrate molecules are changed into products required for life. An enzyme speeds up the process's most challenging stage by securing the substrate to its active site. This activity speeds up a particular chemical reaction.
An enzyme inhibitor halts (or "inhibits") this activity by attaching to the enzyme's active site (preventing the substrate from attaching) or by attaching to another place on the enzyme, preventing the enzyme from catalyzing the reaction. Enzyme inhibitors can bind permanently or reversibly.
The pharmaceutical and nutraceutical sectors depend extensively on enzyme inhibitors. Pharmacologists can build novel therapeutic medications more effectively by using their basic understanding of how inhibitors work. Due to their specificity and the strength of the enzymes they may block, most medications can cure various chronic and fatal conditions. The use of enzyme inhibitors to diagnose a range of disorders fuels the development of inhibitors. Due to the availability of classes of products with enzyme inhibitors and their biochemical features, the therapeutic market for enzyme inhibitors has a very high potential.
The global enzyme inhibitors market report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the enzyme inhibitors market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the enzyme inhibitors market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Enzyme Inhibitors Market Dynamics
The exponential rise in illnesses like cancer, the expanding worldwide agricultural activities, and the expansion of pharmaceutical companies are other factors contributing to the growth of the enzyme inhibitors market. For instance, a complicated multifactorial disease like cancer is brought on by changes in several biochemical and physiological processes. Toxic tumor recurrence can occur when cancer cells develop multidrug resistance to traditional anticancer medications. As a result, there is a constant need to find novel and potent anticancer medications, which is predicted to boost demand for enzyme inhibitors and propel the market's expansion. The pharmaceutical industry's growing trend of product launches, acquisitions, and partnerships also contributes to the market's expansion.
The Cancer Statistics According to American Cancer Society data from 2023, there will be an expected 1.9 million new cancer cases diagnosed and 609,820 cancer deaths in the US during that year. The market is anticipated to increase at an exponential rate due to the exponential rise in the prevalence of illnesses like cancer. In order to develop Novartis' radioligand therapies, Artios Pharma Limited and Novartis International AG worked together in April 2021 to identify and validate next-generation DDR targets. Additionally, in March 2021, Rodeo Therapeutics Corporation was bought by Amgen Inc. Amgen did this because it saw potential in Rodeo's lead 15-prostaglandin dehydrogenase inhibitor product as well as the company's distinct profile.
The market for enzyme inhibitors has seen a rise in the popularity of strategic alliances and collaborations. Major enzyme inhibitor businesses are concentrating on strategic alliances to address consumer demand. For instance, in April 2021, Novartis International AG, a pharmaceutical company with headquarters in Switzerland, joined forces with Artios Pharma Limited, a DNA damage response company with a UK base that also offers enzyme inhibitors, to identify and validate new generation DDR (DNA Damage Response) targets to advance Novartis' Radioligand Therapies (RLT). In order to enhance Novartis' radioligand therapeutics, this relationship with Novartis will be used to identify and evaluate next-generation DDR targets. Additionally, to find novel treatment candidates, Curadev, an Indian pharmaceutical business that makes enzyme inhibitors, and Bayer AG, a German pharmaceutical and life sciences company, joined forces in March 2020.
Enzyme Inhibitors Market Ecosystem
Enzyme Inhibitors Market, by Type
Enzyme Inhibitors Market, by Application
Enzyme Inhibitors Market by Type
[867875]
The kinase inhibitors segment showed a substantial growth during the forecast period. Kinase inhibitors prevent one or more protein kinase enzymes from functioning. Protein kinases are enzymes that change a protein's function by adding a phosphate group. Specific kinases are highly active in some cancer cells, and inhibiting these may help slow cancer cell proliferation. The rise in kinase inhibitors used to treat target diseases, including cancer and cardiovascular disease, as well as their rising prevalence, have been what has been propelling this market's expansion. For instance, according to a report by the British Heart Foundation that was released in February 2023, 7.6 million individuals in the UK had heart disease in 2021.
In addition, 72 Food and Drug Administration (FDA)-approved therapeutic medicines target around two dozen protein kinases. Three of these medications received FDA approval in 2022, according to a National Library of Medicine (NLM) publication released in November 2022. Twelve of the medications that have been approved specifically target protein-serine/threonine kinases; four target dual specificity protein kinases (MEK1/2); sixteen block nonreceptor protein-tyrosine kinases; and forty specifically target receptor protein-tyrosine kinases. Sixty-two of these medications are recommended for the treatment of neoplasms.
The market segmentation sections provide the enzyme inhibitors market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as product, technology, services, end user, and other factors. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential enzyme inhibitors market demand opportunities.
Enzyme Inhibitors Market by Region
The market in North America is expanding due to several reasons, including an advanced healthcare system and a rise in government programs that provide favorable reimbursement terms. The increased prevalence of cancer is significantly influencing the market for enzyme inhibitors. More than 1.9 million new cancer cases are anticipated to be identified in the United States this year, excluding basal and squamous cell skin cancers and carcinoma in situ, with the exception of the urinary bladder. This estimate comes from the American Cancer Society's 2023 update. Similar estimates were made in the Canadian Cancer Statistics 2021 report, which was published in November 2021, with 229,200 Canadians expected to get a cancer diagnosis in 2021. As a result, North America's rising cancer incidence is expected to substantially impact the market's expansion.
Asia Pacific will have the fastest-growing revenue CAGR of 4.5% during the forecasted period. The region's expanding food and pharmaceutical sectors are anticipated to fuel market expansion. Sales of competitive inhibitors are anticipated to soar in Japan because of its food and pharmaceutical sectors, both of which are expanding moderately.
Based on the regions, the global Enzyme Inhibitors market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of enzyme inhibitors industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level enzyme inhibitors market overview.
Key Components of the Report
Enzyme Inhibitors Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Enzyme Inhibitors Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
An enzyme inhibitor is a chemical that attaches to an enzyme and inhibits the enzyme's function. Proteins known as enzymes speed up chemical processes where substrate molecules are changed into products required for life
The North America region will have the largest enzyme inhibitors market size during the forecast period from 2023 to 2031.
The resultant revenue CAGR of the enzyme inhibitors market is expected to have 4.1% during the forecast period.
Technological advancement and product launches are the global enzyme inhibitors market growth opportunities.
The patent expirations of enzyme inhibitor drugs is the main factor hindering the market.
The enzyme inhibitors market is slightly concentrated, with both international and local businesses present. Companies participate in strategic mergers, acquisitions, and partnerships.
The exponential rise in illnesses like cancer and the expanding worldwide agricultural activities are prime driving factors.
Some prominent market players in the global enzyme inhibitors market include Abbott Laboratories, Pfizer Inc., and Boehringer Ingelheim International GmbH, among others.
The kinase inhibitors segment has the highest share in the global enzyme inhibitors market.
*Insights on financial performance are subject to the availability of information in the public domain